DNA vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice

Journal of Immunology

Volumn 165, Issue 9, 2000, Pages 5133-5142

  Rovero, S ^a   Amici, A ^a   Di Carlo, E ^a   Bei, R ^a   Nanni, P ^a   Quaglino, E ^a   Porcedda, P ^a   Boggio, K ^a   Smorlesi, A ^a   Lollini, P L ^a   Landuzzi, L ^a   Colombo, M P ^a   Giovarelli, M ^a   Musiani, P ^a   Forni, G ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE;

ANIMAL CELL; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CARCINOGENESIS; DIMERIZATION; GROWTH INHIBITION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTO ONCOGENE; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; VACCINATION;

EID: 0034326620     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.9.5133     Document Type: Article

References (51)

1. The neu oncogene encodes an epidermal growth factor receptor-related protein
2. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
3. Single-step induction of mammary adenocarcinoma in transgenic mice beating the activated c-neu oncogene
4. C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
5. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein
6. C-erbB2 amplification and overexpression in human tumors
7. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
8. A novel splice variant of HER2 with increased transformation activity
9. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
10. Basic science of Her-2/neu: A review
11. Antiproliferative effect if DNA polymerase alpha antisense oligodeoxynucleotides on breast cancer cells
12. Specific short membrane sequences can inhibit transformation by the mutant neu growth factor receptor in vivo and in vitro
13. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3 and erbB-4 receptors by genetically targeted native T lymphocytes
14. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
15. DNA vaccination encoding full-length or truncated neu induce protective immunity against Neu-expressing mammary tumors
16. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
17. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in en transgenic mice
18. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
19. Genetic immunization against neu/erbB2 transgenic breast cancer
20. Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
21. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice
22. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/2 neu can induce CTL and tumor suppression in syngeneic hosts
23. TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
24. + lymphocyte driven and eosinophil mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4
25. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory
26. Interleukin 12 potentiates the curative effect of a vaccine based on interlelkin2-transduced tumor cells
27. Inverse relationship between anti-SV40 TASA and anti-H-2 cytotoxic responses
28. Alloantigen-activated lymphocytes from mice bearing a spontaneous 'nonimmunogenic' adenocarcinoma inhibit its growth in vivo by recruiting host immune reactivity
29. Immune responses to all ErbB family receptors detectable in serum of cancer patients
30. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune response and protective immunity in mice
31. A rapid simple method for the quantitation of micrograms quantities of protein utilizing the principle-dye binding
32. Analysis of mammary carcinoma onset and progression in Her-2/neu oncogene transgenic mice reveals a lobular origin
33. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic IL-12
34. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
35. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
36. Endothelial vascular cell adhesion molecule I expression is suppressed by melanoma and carcinoma
37. Transport of molecules in the tumor interstitium: A review
38. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells
39. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12
40. Prevention of breast tumors development in vivo by downregulation of the p185neu receptor
41. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
42. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of c-erbB-2 (Her-2/neu) gene product p185
43. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
44. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
45. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
46. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies
47. Secretory IgA antibodies synergize with IgG in promoting ADCC by human polymorphonuclear cells, monocytes and lymphocytes
48. Secretory IgA antibodies synergize with IgG in promoting ADCC by human polymorphonuclear cells, monocytes and lymphocytes
49. Synergy between IgG and monoclonal IgM antibodies in antibody-dependent cell cytotoxicity
50. B cells inhibit induction of T cell-dependent tumor immunity
51. Specific and non-specific immunity in the prevention of spontaneous tumors